Somatostatin Analog Therapy in Small Cell Lung Cancer
Chemotherapy represents the cornerstone of treatment for patients with small cell lung cancer (SCLC); however, standard therapy has reached a plateau in improving patient survival with overall disappointing results. The demonstration that SCLC expresses neuroendocrine markers, such as somatostatin (SST) receptors, has led to use SST analogs or radiolabeled SST analogs in the treatment of SCLC patients. In the current review, we would focus on the possible role of SST analogs in SCLC.
Source: Seminars in Nuclear Medicine - Category: Nuclear Medicine Authors: Alfredo Tartarone, Rosa Lerose, Michele Aieta Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Neurology | Nuclear Medicine | Radiology | Small Cell Lung Cancer